# DNAnexus

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/dnanexus

- Industry: Software
- Headquarters: Mountain View, US
- Website: www.dnanexus.com
- Total disclosed funding: $458M
- Latest round: Series I (Mar 3, 2022)
- Investors on record: 16

## About

DNAnexus, Inc. is a leading provider of cloud-based platforms for precision health data management and analysis, enabling biomedical organizations to optimize data handling and enhance collaboration for research.Founded in 2009 and headquartered in Mountain View, California, DNAnexus focuses on precision health data solutions. The company has received funding from notable investors, including Blackstone Group, which led their most recent Series I funding round in March 2022, raising USD 200.000 mn. The firm has executed nine total deals, with the latest round bringing their total funding to USD 200.000 mn and a current valuation of USD 540.054 mn. The company was co-founded by Serafim Batzoglou, who has a background in computational biology and previously contributed to other startups in the biotech sector.DNAnexus specializes in providing a comprehensive cloud-based platform tailored for precision health data management and analysis. Their core offerings allow biomedical organizations to efficiently manage, analyze, and collaborate on multimodal data sets, which play a crucial role in advancing scientific research and patient care. Key functionalities include streamlined data ingestion, organization, integration of omics datasets, and access to a robust library of bioinformatics tools, enabling users to deploy pipelines and AI/ML algorithms swiftly. The platform is designed to break down data silos by providing a unified source of truth, thereby facilitating seamless collaboration among internal teams and external partners. DNAnexus serves a diverse customer base, including top pharmaceutical companies, academic medical centers, and biobanks, with products that are utilized globally, particularly in North America, Europe, and Asia.DNAnexus generates revenue through subscriptions and strategic partnerships, primarily focusing on B2B transactions. Their business model allows clients, including large pharmaceutical firms and diagnostic companies, to access their platform's capabilities via structured subscription plans that cater to varying levels of service and functionality. The platform's flagship offerings, such as NGS data analysis and translational informatics, drive engagement from clientele, enabling organizations to leverage their data for insightful analysis and decision-making. Revenue is derived from subscription fees that provide clients access to the tools and services necessary for effective genomic computing and data management, ensuring compliance with industry regulations and standards. The company’s commitment to delivering immediate time-to-value enhances its attractiveness to clients seeking efficiency in their research processes.DNAnexus plans to utilize proceeds from the March 2022 Series I funding, amounting to USD 200.000 mn, to accelerate its genomics platform, enhance its global growth, and incorporate new AI and machine learning technologies. The company is focused on expanding its offerings and entering new markets, aiming to reach broader segments within Europe and Asia by 2024. This strategy aligns with their commitment to improve precision health outcomes through advanced technological integration.

## Funding rounds

- Series I, Mar 3, 2022, $200M — Blackstone Group, GV, Foresite Capital, Perceptive Advisors, Innovatus Capital Partners, Northpond Ventures
- Series H, Jun 5, 2020, $100M — First Round Capital, TPG Biotech, GV, Foresite Capital, Perceptive Advisors, Regeneron Pharmaceuticals, Inc., Northpond Ventures
- Series F, Jun 24, 2019, $68M — Claremont Creek Ventures, TPG Biotech, GV, Foresite Capital, NextCODE, Innovatus Capital Partners
- Series E, Jan 2, 2018, $58M — Claremont Creek Ventures, TPG Biotech, GV, Foresite Capital, MidCap Financial, NextCODE
- Series C, Dec 20, 2013, $15M — Claremont Creek Ventures, First Round Capital, TPG Biotech, GV
- Series B, Oct 12, 2011, $15M — First Round Capital, TPG Biotech, GV, K9 Ventures, Felicis Ventures, Uncork Capital
- Series A, May 13, 2009, $1.6M — First Round Capital, K9 Ventures, Felicis Ventures, SV Angel, Uncork Capital

## Investors

- First Round Capital (https://capitalatlas.ai/funds/first-round-capital) — Series A, Series B, Series C, Series H
- K9 Ventures (https://capitalatlas.ai/funds/k9-ventures) — Series A, Series B
- Felicis Ventures (https://capitalatlas.ai/funds/felicis-ventures) — Series A, Series B
- SV Angel (https://capitalatlas.ai/funds/sv-angel) — Series A
- Uncork Capital (https://capitalatlas.ai/funds/uncork-capital) — Series A, Series B
- TPG Biotech (https://capitalatlas.ai/funds/tpg-biotech) — Series B, Series C, Series E, Series F, Series H
- GV (https://capitalatlas.ai/funds/gv) — Series B, Series C, Series E, Series F, Series H, Series I
- Claremont Creek Ventures (https://capitalatlas.ai/funds/claremont-creek-ventures) — Series C, Series E, Series F
- Foresite Capital (https://capitalatlas.ai/funds/foresite-capital) — Series E, Series F, Series H, Series I
- MidCap Financial — Series E
- NextCODE — Series E, Series F
- Innovatus Capital Partners (https://capitalatlas.ai/funds/innovatus-capital-partners) — Series F, Series I
- Perceptive Advisors (https://capitalatlas.ai/funds/perceptive-advisors) — Series H, Series I
- Regeneron Pharmaceuticals, Inc. — Series H
- Northpond Ventures (https://capitalatlas.ai/funds/northpond-ventures) — Series H, Series I
- Blackstone Group (https://capitalatlas.ai/funds/blackstone-group) — Series I